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Neuroprotection of Neuro2a cells and the cytokine suppressive and antiinflammatory mode of action of resveratrol in activated RAW264.7 macrophages
and C8-B4 microglia
Abstract
Chronic inflammation is a hallmark of neurodegenerative disease and cytotoxic levels of nitric oxide (NO)
and pro-inflammatory cytokines can initiate neuronal death pathways. A range of cellular assays were
used to assess the anti-inflammatory and neuroprotective action of resveratrol using murine microglial
(C8-B4), macrophage (RAW264.7) and neuronal-like (Neuro2a) cell lines. We examined the release of NO
by Griess assay and used a Bioplex array to measure a panel of pro- and anti-inflammatory cytokines and
chemokines, in response to the inflammatory stimuli lipopolysaccharide (LPS) and interferon-γ (IFN-γ).
Resveratrol was a potent inhibitor of NO and cytokine release in activated macrophages and microglia.
The activity of resveratrol increased marginally in potency with longer pre-incubation times in cell culture
that was not due to cytotoxicity. Using an NO donor we show that resveratrol can protect Neuro2a cells
from cytotoxic concentrations of NO. The protective effect of resveratrol from pro-inflammatory signalling
in RAW264.7 cells was confirmed in co-culture experiments leading to increased survival of Neuro2a
cells. Together our data are indicative of the potential neuroprotective effect of resveratrol during
nitrosative stress and neuroinflammation.

Publication Details
Steiner, N., Balez, R., Karunaweera, N., Lind, J. M., Münch, G. & Ooi, L. (2016). Neuroprotection of Neuro2a
cells and the cytokine suppressive and anti-inflammatory mode of action of resveratrol in activated
RAW264.7 macrophages and C8-B4 microglia. Neurochemistry International: the journal for the
publication of cellular and molecular aspects of neurochemistry, 95 46-54.

Authors
Nicole Steiner, Rachelle Balez, Niloo Karunaweera, Joanne M. Lind, Gerald Münch, and Lezanne Ooi

This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers/3719

Neurochemistry International 95 (2016) 46e54

Contents lists available at ScienceDirect

Neurochemistry International
journal homepage: www.elsevier.com/locate/nci

Neuroprotection of Neuro2a cells and the cytokine suppressive and
anti-inﬂammatory mode of action of resveratrol in activated
RAW264.7 macrophages and C8eB4 microglia
Nicole Steiner a, Rachelle Balez b, Niloo Karunaweera a, Joanne M. Lind c,
Gerald Münch a, d, e, Lezanne Ooi b, *
a

Dept of Pharmacology, School of Medicine, University of Western Sydney, Locked Bag 1797, Penrith, NSW, Australia
Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, NSW 2522, Australia
School of Medicine, Western Sydney University, Locked Bag 1797, Penrith, NSW, Australia
d
National Institute of Complementary Medicine (NICM), Western Sydney University, Australia
e
Molecular Medicine Research Group, University of Western Sydney, Australia
b
c

a r t i c l e i n f o

a b s t r a c t

Article history:
Received 13 March 2015
Received in revised form
8 September 2015
Accepted 24 October 2015
Available online 29 October 2015

Chronic inﬂammation is a hallmark of neurodegenerative disease and cytotoxic levels of nitric oxide (NO)
and pro-inﬂammatory cytokines can initiate neuronal death pathways. A range of cellular assays were
used to assess the anti-inﬂammatory and neuroprotective action of resveratrol using murine microglial
(C8eB4), macrophage (RAW264.7) and neuronal-like (Neuro2a) cell lines. We examined the release of
NO by Griess assay and used a Bioplex array to measure a panel of pro- and anti-inﬂammatory cytokines
and chemokines, in response to the inﬂammatory stimuli lipopolysaccharide (LPS) and interferon-g (IFNg).
Resveratrol was a potent inhibitor of NO and cytokine release in activated macrophages and microglia.
The activity of resveratrol increased marginally in potency with longer pre-incubation times in cell
culture that was not due to cytotoxicity. Using an NO donor we show that resveratrol can protect
Neuro2a cells from cytotoxic concentrations of NO. The protective effect of resveratrol from proinﬂammatory signalling in RAW264.7 cells was conﬁrmed in co-culture experiments leading to
increased survival of Neuro2a cells. Together our data are indicative of the potential neuroprotective
effect of resveratrol during nitrosative stress and neuroinﬂammation.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Chronic inﬂammation is known to be an important etiological
condition for various chronic diseases, including atherosclerosis,

Abbreviations: COX-2, cyclooxygenase-2; CSAIDs, cytokine suppressing antiinﬂammatory drugs; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; JNK,
c-Jun N-terminal kinase; LPS, lipopolysaccharide; MAPK, mitogen activated protein
kinase; Mip-1a, macrophage inﬂammatory protein-1a; NF-kB, nuclear factor-kB;
NO, nitric oxide; NSAIDs, non-steroidal anti-inﬂammatory drugs; SNAP, S-NitrosoN-acetyl-DL-penicillamine.
* Corresponding author. Illawarra Health and Medical Research Institute, School
of Biological Sciences, Building 32, University of Wollongong, Northﬁelds Avenue,
Wollongong NSW 2522, Australia.
E-mail address: lezanne@uow.edu.au (L. Ooi).

diabetes, and arthritis. Furthermore, increasing evidence suggests
that innate immune activation is a major component of age-related
neurodegenerative diseases, such as Alzheimer's and Parkinson's
disease (for recent reviews see (Heneka et al., 2014; Norden et al.,
2015)).
Inﬂammatory cells, including macrophages and microglia, play a
major role in the body's response to immunogenic challenges, by
re-establishing tissue homeostasis, producing large amounts of
superoxide, nitric oxide (NO) and pro-inﬂammatory cytokines that
aggravate and propagate inﬂammation and disrupt the normal
function of cells. For example, the pro-inﬂammatory cytokine,
tumour necrosis factor-a (TNF-a), binds to two tumour necrosis
factor receptors TNFR1 and TNFR2 and, depending on the adaptor
protein, activates various signalling pathways including nuclear
factor-kB (NF-kB), and the mitogen activated protein kinases
(MAPK), p38 and c-Jun N-terminal kinase (JNK), which can lead to

http://dx.doi.org/10.1016/j.neuint.2015.10.013
0197-0186/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

N. Steiner et al. / Neurochemistry International 95 (2016) 46e54

proliferation, cell migration, apoptosis and necrosis (McCoy and
Tansey, 2008).
NO is a signalling molecule with diverse cellular roles; it is
released by macrophages, neurons and endothelial cells and can
be either protective or toxic to cells depending on the cellular
context (Ooi et al., 2013a; Gamper and Ooi, 2015). The toxicity of
NO is attributed to its ability to bind to proteins that contain
heme, iron, copper or organic side groups, such as thiols,
resulting in protein disruption and alterations in cellular activities. As a result of reactivity with a wide range of cellular
components, high levels of NO are toxic to neurons, while low
levels can be neuroprotective (Balez and Ooi, 2015). Similarly
there is evidence that activation of microglia could have a protective role in neurodegenerative diseases (Luo and Chen, 2012;
Kan et al., 2015). Therefore promoting anti-inﬂammatory cytokines or limiting pro-inﬂammatory cytokine and NO production
by activated macrophages/microglia should be beneﬁcial for
prevention of systemic and local inﬂammation and would be
potentially neuroprotective.
To date, pharmacotherapy of inﬂammatory conditions is
based on the use of non-steroidal anti-inﬂammatory drugs
(NSAIDs). However, NSAIDs can cause serious gastrointestinal
toxicity such as gastric bleeding and the formation of stomach
ulcers. Some NSAIDs, particularly cyclooxygenase-2 (COX-2) inhibitors, have been linked to increased blood pressure, greatly
increased risk of congestive heart failure, thrombosis and
myocardial infarction (Mitchell and Warner, 2006). NSAIDs are
inhibitors of cyclooxygenase and speciﬁcally suppress the production of prostaglandins (Vane et al., 1998). Thus the identiﬁcation of anti-inﬂammatory treatments with fewer adverse
effects and drugs with broader anti-inﬂammatory properties is
an important task. One such therapeutic approach involves
suppressing the production of interleukin-1 (IL-1), TNF-a and
other NF-kB regulated cytokines at the level of transcription,
translation and/or secretion. The activities associated with
certain of pyridinyl imidazoles involve a class of compounds
referred to as cytokine suppressing anti-inﬂammatory drugs
(CSAIDs) (Karunaweera et al., 2015).
The stilbene resveratrol (3,40 ,5-trihydroxy-trans-stilbene) is a
polyphenol CSAID found in grapes, red wine, mulberries knotweed, peanuts and other plants. Resveratrol dampens inﬂammation in arthritis (Elmali et al., 2007) and immune
responsiveness in autoimmune disease (Singh et al., 2010).
Resveratrol can also penetrate the blood brain barrier in vivo
(Baur et al., 2006), however the effect of resveratrol on a broad
range of pro- and anti-inﬂammatory factors has not previously
been investigated.
In the present study, we ﬁrst examined the expression of various
pro- and anti-inﬂammatory cytokines, chemokines and NO by
murine microglia (C8eB4) and macrophages (RAW264.7) in
response to the inﬂammatory stimuli lipopolysaccharide (LPS) and
interferon-g (IFN-g). We then determined the effects of resveratrol
on cytokines and chemokines in activated C8eB4 microglia and
RAW264.7 macrophages and investigated the effect of the preincubation time in cell culture on the calculated potency. Resveratrol potently inhibited the release of NO and a number of cytokines
from activated macrophages and microglia and was able to protect
neuronal-like Neuro2a cells from cytotoxic concentrations of NO.
Conditioned media from activated RAW264.7 cells reduced the
viability of Neuro2a cells, an effect that was prevented by pretreatment of the activated RAW264.7 cells with resveratrol.
Together our results highlight the anti-inﬂammatory effects of
resveratrol and its potential as a neuroprotective agent against
neuroinﬂammation.
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2. Materials and methods
2.1. Materials
The 23-multiplex cytokine assay was from Bio-rad (Gladesville,
Australia). All cell culture materials were from Invitrogen (Mulgrave, Australia). Cell culture plasticware including Primaria plates
was from Greiner Bio-One (Frickenhausen, Germany), Protease inhibitor cocktail, naphthyethylene-diamine, sulfanilamide, Corning®
Costar® Spin-X® spin ﬁlter, LPS (from Salmonella enteric serotype
thyphimurium), resazurin and S-Nitroso-N-acetyl-DL-penicillamine (SNAP) were from SigmaeAldrich (Castle Hill, Australia).
Interferon-g was from Pepro Tech (Rocky Hill, USA). TrypLE Express™ was purchased from Life Technologies (Mulgrave,
Australia). Cell lines were obtained from the ATCC.
2.2. Cell maintenance
RAW264.7, C8eB4 and Neuro2a cells were maintained in DMEM
containing 25 mM glucose, supplemented with 200 U/ml penicillin,
200 mg/ml streptomycin, 200 mM glutamine (GlutaMax, Gibco) and
10% fetal bovine serum. Cells were grown in 75 cm2 tissue culture
ﬂasks and incubated at 37  C in 5% CO2. RAW264.7 and Neuro2a
cells were detached from the ﬂask with a rubber policeman and
split 1:10 every 5 days. C8eB4 cells were split 1:2 every 2 weeks
and partial medium changes were performed twice a week.
2.3. Resveratrol treatment of LPS and IFN-g activated C8eB4 and
RAW264.7 cells and SNAP-treated Neuro2a cells
Cells were washed twice with PBS and harvested with TrypLE
Express. Cells were then plated in a 96-well plate at a density of
60,000 cells/well and incubated for 24 h before treatment. Cells
were pre-treated with resveratrol for 1 h before adding the activation mix containing 12.5 mg/ml LPS and 5 Units IFN-g for 24 h. The
total volume of medium in each well was 100 ml and to obtain
enough supernatant for further analysis, the supernatant from 3
wells was combined. The supernatant was spin ﬁltered (0.2 mm
Corning spin ﬁlter) and 0.4 ml protease inhibitor cocktail containing
Aprotinin, Bestatin, E64, Leupeptin and Pepstatin A (Sigma) was
added. Fifty microlitres of supernatant was immediately used for
measuring NO and the remainder was stored at 80  C for later
analysis by cytokine array. Neuro2a cells were pre-treated with
resveratrol for 1 h before treatment with the NO donor, SNAP, at
concentrations ranging from 0.1 to 1000 mM or the vehicle control
(DMSO). Cells were harvested for cell viability assays and the supernatant collected for Griess assay to measure nitrite
concentration.
2.4. Neuro2a incubation with conditioned media from activated
RAW264.7 cells
As in Section 2.3 RAW264.7 cells were plated at a density of
60,000 cells/well and incubated for 24 h before treatment.
RAW264.7 cells were activated with 12.5 mg/ml LPS and 5 Units IFNg for 24 h. Cells were pre-treated with 100 mM resveratrol or vehicle
control (DMSO) for 1 h prior to inﬂammatory activation. Neuro2a
cells were seeded at a density of 60,000 cells per well in a 96-well
plate, and incubated for 24 h. Media from RAW264.7 cells were
added to Neuro2a cells. As a further control, Neuro2a cells were also
pre-treated with 100 mM resveratrol or vehicle control (DMSO) for
1 h prior to application of RAW264.7 conditioned media. After 24 h
of incubation with conditioned media from RAW264.7 cells, the
Neuro2a cells were assessed by cell viability and Griess assay. The
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same measurements were simultaneously taken for the RAW264.7
cells.
2.5. Resazurin-based assay for determination of cell viability
Cell viability was assessed in terms of the metabolic capability of
cells to convert the non-ﬂuorescent redox indicator, resazurin, into
its highly ﬂuorescent product, resoruﬁn. DMEM (100 ml) containing
0.125 mg/l resazurin was added to each well of a 96-well plate and
incubated for 90 min a 37  C. Fluorescence was measured at 560 nm
excitation/590 nm emission using a BMG Labtech POLARstar
Omega ﬂuorescent plate reader (BMG LABTECH, Ortenberg,
Germany).
2.6. Nitrite determination by Griess assay
The nitrite concentration in the culture medium was measured
as an indicator of NO production using the Griess reaction. Supernatant from each well (50 ml) was transferred to a fresh 96 well
plate and 25 ml of 1% sulfanilamide plus 25 ml of 0.1%
napthyethylene-diamine in 5% HCl were added. When combined,
these compounds (known as Griess reagent), form a violet colour in
the presence of nitrite. After 10 min incubation at room temperature, the absorbance of each well was measured at 540 nm using a
Bio-Rad Model 680 Microplate reader (Bio-Rad, Gladesville,
Australia). Nitrite concentration was calculated with reference to a
standard curve of sodium nitrite generated by known concentrations, ranging from 0 to 100 mM.
2.7. Determination of cytokine levels using a Bioplex cytokine assay
A panel of 23 cytokines was measured, using a Bioplex Pro™
mouse cytokine 23-plex kit (Bio-Rad, Gladesville, Australia), according to the manufacturer's protocol.
2.8. Data analysis
The standard error of the mean (SEM) and all other values were
calculated from at least three independent experiments. Signiﬁcant
differences were assessed by one-way ANOVA with Tukey's multiple comparisons test. IC50 values for resveratrol were calculated
using the sigmoidal doseeresponse function.
3. Results
3.1. LPS and IFN-g activation increases NO and cytokine/chemokine
release in murine RAW264.7 and C8eB4 cells
For the determination of the potency of a CSAID, cell lines with a
broad range of cytokine and chemokine response are needed. These
cell lines should react upon stimulation with pro-inﬂammatory
stimuli, such as LPS and IFN-g, with up-regulation of inducible nitric oxide synthase (with resulting NO production and release), as
well as increased expression and release of pro-inﬂammatory cytokines such as TNF-a, interleukin-1a (IL-1a), IL-1b, IL-6, IL-12, as
well as chemokines such as granulocyte colony-stimulating factor
(G-CSF).
When both cell lines were activated with a combination of LPS
and IFN-g, a signiﬁcant increase in NO production (determined as
nitrite) was observed. The activated macrophage cell line
RAW264.7 released approximately four times more NO compared
to C8eB4 cells (Table 1). In addition, 17 different inﬂammatory
markers were determined using the Bioplex Pro™ mouse cytokine
23-plex immunoassay (6 markers were below detection threshold;
Table 1).

In both cell lines, activation with LPS and IFN-g for 24 h led to a
signiﬁcant up-regulation of the pro-inﬂammatory cytokines IL-1a,
IL-6, TNF-a, IL-12(p40) and the chemokines G-CSF and CeC motif
chemokine 5 (CCL5, also known as RANTES). Activation also upregulated the anti-inﬂammatory cytokines IL-10 and IL-13 in
RAW264.7 macrophage cells but not in C8eB4 microglia. The chemokines monocyte chemotactic protein 1 (MCP-1), macrophage
inﬂammatory protein-1a (Mip-1a), Mip-1b, were also only upregulated in RAW 264.7, but not in C8eB4 microglia. In general,
the C8eB4 cells showed a more limited cytokine/chemokine
release repertoire than the RAW264.7 cells under the same activation conditions (Table 1).
3.2. Resveratrol prevents NO and cytokine release in RAW264.7 and
C8eB4 cells but has a limited effect on chemokine release
To answer the question as to whether resveratrol possesses
broad anti-inﬂammatory actions, cells were pre-incubated with
resveratrol at concentrations up to 100 mM for 1 h prior to activation by LPS and IFN-g in RAW264.7 and C8eB4 cells, after which the
release of NO, cytokines and chemokines was measured. Only those
pro-inﬂammatory markers that had shown an up-regulation of
>1.5 fold in the previous experiment were analysed. An antiinﬂammatory effect of resveratrol (deﬁned as an IC50
value < 100 mM) could be demonstrated in both cell lines. Resveratrol down-regulated the pro-inﬂammatory cytokines IL-1a, IL-1b,
IL-6 and TNF-a in both RAW264.7 and C8eB4 cells. However, it
also down-regulated the anti-inﬂammatory cytokine IL-10 in
RAW264.7 cells only (Table 2). Resveratrol effects on chemokines
were more limited, leading to down-regulation of only MCP-1 and
RANTES in RAW264.7 (Table 3).
3.3. Increasing pre-incubation time marginally increases potency of
resveratrol
Since the effects of inﬂammatory activation were more potent in
the RAW264.7 cells and since resveratrol was more effective in
limiting inﬂammatory activation of RAW264.7 cells, we continued
our experiments using this cell line only. One of the most fundamental questions to judge the clinical efﬁcacy of a compound is
whether the concentration of the compound in the human body is
in the same order of magnitude as its IC50 value. However, it might
be possible that some cell culture experiments are also conducted
under suboptimal conditions, and effective concentrations are
higher than needed. For example, a very short pre-incubation time
might make it impossible or difﬁcult for the compound to reach an
intracellular target, whereas long pre-incubation times might lead
to substantial degradation of the compound.
We wanted to determine whether our experimental setup of 1 h
pre-incubation time affected potency, resulting in limited diffusion
of resveratrol into the cell. We hypothesized that the calculated
potency might increase when the incubation time was extended. To
answer this question, RAW264.7 cells were pre-incubated with
resveratrol for 1, 3, 6, 9 and 24 h before activation with LPS and IFNg. NO was measured after 24 h to assess the potency of resveratrol.
In these experiments the calculated IC50 decreased from
44.7 ± 7.1 mM after 1 h pre-incubation to 26.7 ± 3.5 mM after 6 h preincubation, increasing after 24 h pre-incubation (Fig. 1). To exclude
the possibility that the decrease in the release of the proinﬂammatory markers were caused by cell death, cytotoxicity of
resveratrol was measured in RAW264.7 and C8eB4 cells. At preincubation times of 1 h, and concentrations below 100 mM,
resveratrol did not show cytotoxicity in RAW264.7 cells. Only at a
concentration of 110 mM did resveratrol cause a decrease in cell
viability by 13% in C8eB4 cells (data not shown). The LC50 values
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Table 1
Comparison of cytokine & chemokine responses to activation with LPS and IFN-g in RAW264.7 and C8-B4 cells. Data are shown as mean concentration (pg/ml) ± SEM from 3
independent experiments and fold change. Underline denotes anti-inﬂammatory cytokines. Signiﬁcant difference between unactivated and activated cells denoted as
* ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001, ns ¼ not signiﬁcant.
Inﬂammatory response marker

Concentration in RAW 264.7
macrophages (pg/ml)
Unactivated

Nitric oxide (mM)
IL-1 a
IL-1 b
IL-6
IL-9
IL-12(p40)
IL-12(p70)
TNF-a
G-CSF
GM-CSF
IL-10
IL-13
Eotaxin
KC
MCP-1
Mip-1a
Mip-1b
RANTES

1.0
46.0
2585
12
1195
44
413
237
25
417
91
749
1430
23
534
66979
13336
150

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.4
1.4
149
3
133
6
15
5
1
9
3
19
63
2
69
6675
1089
3

Upregulation (fold)

Activated
60
331
3203
10522
2132
88
1252
142870
113944
716
10358
2105
4234
55
45626
177204
538430
35472

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

Concentration in C8-B4 microglia
(pg/ml)
Unactivated

4
21
81
822
224
6
22
8619
12150
22
765
50
414
2
5286
22988
3531
3226

60***
7***
1.2*
877***
1.8**
2.0**
3.0***
603***
4558***
1.7***
114***
3.0***
3.0***
2.4***
85***
2.6*
40***
236***

1.3
17
1502
21
140
129
314
304
155
302
122
876
1928
20
23226
4559
12933
92

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.3
2
48
5
3
11
29
60
64
25
7
42
134
1
1794
582
622
41

Upregulation (fold)

Activated
16.4
158
1459
572
154
1051
286
9395
7070
375
117
915
2399
47
26115
5526
9336
752

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.8
37
277
117
11
234
74
2085
2191
46
23
196
260
7
8948
3711
2573
226

13***
9.3**
ns
27**
ns
8.1**
ns
31**
46**
ns
ns
ns
ns
2.3**
ns
ns
ns
8*

Table 2
Effect of resveratrol on cytokine levels in RAW264.7 and C8eB4 cells. Data shown
are mean IC50 of resveratrol (mM) ± SEM from 3 independent experiments, n.d. ¼ not
determined. Underline denotes anti-inﬂammatory cytokines.
Cytokine

Cells

IC50 (mM)

IL-1a

RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4

95 ± 11
68 ± 15
53 ± 14
99 ± 21
>136
>110
>136
>110
>136
n.d.
62 ± 8
42 ± 6
>136
50 ± 6
>136
60 ± 11
37 ± 2
>110

IL-6
IL-9
IL-12(p40)
IL-12(p70)
TNF-a
G-CSF
GM-CSF
IL-10

(lethal concentration at which 50% of the cells were killed)
remained the same in all pre-treatment ranges but increased only
after 24 h pre-treatment (Table 4). The increase in NO production at
Table 3
Effect of resveratrol on chemokine levels in RAW264.7 and C8eB4 cells. Data shown
are mean IC50 of resveratrol (mM) ± SEM from 3 independent experiments, n.d. ¼ not
determined.
Chemokine

Cells

IC50 (mM)

Eotaxin

RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4
RAW264.7
C8eB4

>136
n.d.
>136
>110
77 ± 7
>110
>136
>110
>136
>110
63 ± 7
>110

KC
MCP-1
Mip-1a
Mip-1b
RANTES

Fig. 1. The effect of resveratrol pre-incubation time on inhibition of NO release.
Dose response curves for resveratrol induced down-regulation of nitrite in RAW264.7
cells with different pre-incubation times prior to inﬂammatory activation with LPS and
IFN-g. Data shown are mean ± SEM, n ¼ 3.

24 h pre-treatment was therefore likely due to an increase in cell
number following 24 h pre-incubation. Our data suggest that the
calculated potency of resveratrol increases 1.6 fold with increasing
pre-incubation times and this is not due to an alteration in cell
viability.
3.4. Resveratrol protects Neuro2a cells from cytotoxic levels of NO
The neuroprotective and neurodegenerative capacity of inﬂammatory cells are central to understanding pathways pertinent
to neuronal survival. Identifying molecules that promote neuronal
survival is central to preventing neurodegeneration. The simplest
way to study these effects is to remove contributing factors and
study one component of the system. To determine whether
resveratrol could be neuroprotective against cytotoxic concentrations of NO, Neuro2a cells were treated with 1 mM resveratrol for
6 h prior to incubation with the NO donor, SNAP. This concentration
was chosen based on our previous experiments in Neuro2a cells
and because resveratrol reaches nanomolar to micromolar concentrations in the plasma and brain (Nguyen et al., 2013; Walker
et al., 2014). SNAP incubation at concentrations of 0.1 and 1 mM
did not increase nitrite levels above vehicle control, as measured by
Griess assay (no signiﬁcant difference from control). SNAP at concentrations of 10, 100 and 1000 mM increased nitrite levels in
Neuro2a media by 4, 15 and 100 fold, respectively (Fig. 2), with no
signiﬁcant difference in nitrite levels measured in the media from
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Table 4
IC50 and LC50 values for resveratrol at different pre-incubation times in RAW264.7.
Data shown are mean ± SEM, n ¼ 3.
Pre-incubation time (h)

IC50 for NO inhibition (mM)

1
3
6
9
24

44.7
39.7
26.7
28.0
53.6

±
±
±
±
±

7.1
5.7
3.5
3.6
17.4

LC50 (mM)
143.7
153.8
152.6
141.9
249.4

±
±
±
±
±

18.8
17.0
20.5
29.8
165.4

cells treated with resveratrol compared to control. Concentrations
ranging from 0.1 to 100 mM SNAP had no effect on Neuro2a cell
viability, while 1000 mM SNAP was neurotoxic, reducing cell
viability by 22 ± 5% (p < 0.05, n ¼ 3; Fig. 3) compared to vehicle
control. Even at the lowest concentration of resveratrol tested in
macrophages and microglia (1 mM) resveratrol was able to protect
Neuro2a against cytotoxic concentrations of NO and nitrosative
stress (Fig. 3). Resveratrol increased cell viability in the presence of
10, 100 and 1000 mM SNAP by 2.7, 2.9 and 2.1 fold, respectively, and
was thus able to prevent the cytotoxic effects of 1000 mM SNAP.
Since resveratrol was able to protect cells against cytotoxic
concentrations of NO, we further investigated its potential as a
neuroprotective agent. The neuroprotective effect of resveratrol
was tested in a macrophage-neuron co-culture experiment using
the transfer of conditioned media, as described previously (Münch
et al., 2003). Media were incubated with RAW264.7 cells for 24 h
and then incubated with Neuro2a cells. RAW264.7 cells were pretreated with 100 mM resveratrol or vehicle control (DMSO) for 1 h
prior to inﬂammatory activation and activated with 12.5 mg/ml LPS
and 5 Units IFN-g for 24 h, as in the previous experiments. Media
from RAW264.7 cells were added to Neuro2a cells and after 24 h
incubation cell viability and Griess assays were performed for the
RAW264.7 and Neuro2a cells. As expected, inﬂammatory activation
of RAW264.7 cells led to a dramatic up-regulation of nitrite in the
media of RAW264.7 cells (Fig. 4A). Nitrite remained at similar levels
24 h after transfer of the media to the Neuro2a cells (Fig. 4B). Preincubation of the RAW264.7 cells with 100 mM resveratrol prevented increases in nitrite that remained present in the media that
was transferred to the Neuro2a cells and incubated for 24 h (Fig. 4A,
B). Resveratrol treatment alone on RAW264.7 (without inﬂammatory activation) had no effect on the viability of Neuro2a cells
(Fig. 5A). Conversely, inﬂammatory activation of RAW264.7 led to a
reduction in Neuro2a viability that was reduced by pre-incubation
of RAW264.7 with resveratrol. As further controls, media containing the inﬂammatory mixes, with or without resveratrol were
added direct to the Neuro2a cells in the absence of incubation with
RAW264.7 cells (Fig. 5B). Application of this media had no signiﬁcant effect on viability of Neuro2a cells in any of the conditions,
showing that the reduction in Neuro2a viability was caused by

Fig. 2. Quantitation of nitrite following incubation with the NO donor SNAP.
Neuro2a cells were incubated with 1 mM resveratrol or vehicle control for 6 h prior to
treatment with vehicle or 0.1, 1, 10, 100 or 1000 mM of the NO donor SNAP and incubated for 24 h. Nitrite levels in the cell media were measured by Griess assay. Data
shown are mean ± SEM, n ¼ 3.

Fig. 3. The effects of the NO donor SNAP on cell viability following pre-treatment
with resveratrol. Neuro2a cells were incubated with 1 mM resveratrol or vehicle
control for 6 h prior to treatment with vehicle or 0.1, 1, 10, 100 or 1000 mM of the NO
donor SNAP and incubated for 24 h. Cell viability was measured by resazurin assay.
Data shown are mean ± SEM, n ¼ 3. Signiﬁcant interactions were determined by twoway ANOVA; # denotes p < 0.05 SNAP treatment compared to vehicle control; * denotes p < 0.05 resveratrol treatment compared to vehicle control.

molecules secreted by activated RAW264.7 cells. In addition, Neuro2a cells were pre-treated with 100 mM resveratrol or vehicle
control (DMSO) for 1 h prior to application of RAW264.7 conditioned media (Figs. 4 and 5). This treatment had no further effect on
nitrite levels or Neuro2a viability, suggesting that the neuroprotective effects observed were speciﬁcally due to the antiinﬂammatory effects of resveratrol on RAW264.7 cells. Together
these data highlight the potential neuroprotective role for the action of resveratrol via its anti-inﬂammatory actions, in addition to
its ability to protect against cytotoxic levels of NO.
4. Discussion
4.1. RAW264.7 macrophages exhibited a more reactive phenotype
than C8eB4 microglia, releasing higher levels of nitric oxide and
pro-inﬂammatory cytokines
During brain inﬂammation, the microglia proliferate and
migrate to the inﬂammatory lesion (Kettenmann et al., 2011). Blood
derived macrophages may also enter the brain via the blood brain
barrier. (Guillemin and Brew, 2004). In the central nervous system
two different macrophage populations have a role to play in supporting neurons, and these are often described as CNS-resident
microglia and CNS-inﬁltrating peripheral macrophages. In neurodegenerative diseases, such as Alzheimer's disease, CNS-inﬁltrating
peripheral macrophages may contribute to neurodegeneration,
however activated microglia may also protect neurons by removing
toxic aggregates and cellular debris (Kraft and Harry, 2011). Functional differences in CNS-resident microglia and acutely inﬁltrating
inﬂammatory macrophages have been identiﬁed (Carson et al.,
2007). Thus an understanding of cell-type speciﬁc effects and the
differences in commonly used cellular models of macrophages and
microglia is important to identify the roles these cells play in
neuroprotection/neurodegeneration (Simard et al., 2006).
Activated microglia behave similarly to macrophages by
inducing cytotoxicity in a variety of cells through the release of NO
(Brantley et al., 2010). It is likely that some microglia develop from
a pool of blood monocytes and colonize the brain early in development (Lawson et al., 1990, 1992). Evidence suggests that LPS and
IFN-g-activated microglia isolated from the adult brain are more
similar to macrophages inﬁltrating the CNS than naive microglia of
the brain (Schmid et al., 2009). Therefore it is important to
consider the responses of each of these cell types to activation and
the effects of any neuroprotective agents in preventing these responses. To address this we have carried out a comprehensive
study on the anti-inﬂammatory effects of resveratrol, a polyphenol
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Fig. 4. Inﬂammatory activation of RAW264.7 cells caused increases in nitrite measured by Griess assay. (A) Griess assay on RAW264.7 cells treated with LPS and IFN-g for
24 h ± 1 h pre-incubation with resveratrol (100 mM) in RAW264.7 cells. Samples were untreated, treated with vehicle (veh) or resveratrol (resv) ± inﬂammatory activation (inﬂam;
LPS and IFN-g). (B) The media was transferred from RAW264.7 cells to Neuro2A cells and incubated with Neuro2A cells for 24 h prior to Griess assay. To conﬁrm the effects were
driven by resveratrol on the RAW264.7 cells rather than on Neuro2A cells, Neuro2A cells were also pre-treated with vehicle or resveratrol prior to application of the RAW264.7
media (Veh (pre-treat) þ inﬂam; Resv (pretreat) þ Inﬂam). Data shown are mean ± SEM, n ¼ 4.

Fig. 5. Conditioned media from inﬂammatory activated RAW264.7 cells reduced viability of Neuro2A cells, which could be prevented with resveratrol treatment of
RAW264.7 cells. (A) Cell viability of RAW264.7 cells 24 h following treatment with inﬂammatory activators (inﬂam; LPS and IFN-g) ± pre-incubation for 1 h with vehicle (veh) or
resveratrol (resv) as in Fig. 4. To conﬁrm the effects were driven by resveratrol on the RAW264.7 cells rather than on Neuro2A cells, Neuro2A cells were also pre-treated with vehicle
or resveratrol prior to application of the RAW264.7 media (Veh (pre-treat) þ inﬂam; Resv (pretreat) þ Inﬂam). (B) Cell viability of Neuro2A cells was measured following transfer of
the same media mixes as in (A) but these were added directly to the Neuro2a cells in the absence of incubation with RAW264.7 cells. Data shown are mean ± SEM, n¼4.

present in grape skin, artichoke and basil, with purportedly neuroprotective actions (reviewed in (Jayasena et al., 2013)). To study
the effects of resveratrol we compared macrophage and microglial
cell lines during activation by LPS and IFN-g. Both cell lines
expressed a panel of pro-inﬂammatory cytokines following activation, though C8eB4 microglial cells were more limited in their
repertoire. RAW264.7 macrophages released higher levels of 15
out of 17 cytokines tested and four times as much NO (measured
as nitrite) compared to C8eB4 microglial cells. Therefore
RAW264.7 macrophages show a more reactive phenotype than C8B4 cells following activation with the same concentrations of LPS
and IFN-g.
4.2. Resveratrol exhibits anti-inﬂammatory properties
Resveratrol reduced 7 out of 9 pro-inﬂammatory cytokines from
C8eB4 cells and 5 out of 9 pro-inﬂammatory cytokines from
RAW264.7 cells. It also signiﬁcantly reduced nitrite levels in both
lines, but had a more limited effect on chemokine release, reducing

only MCP-1 and RANTES in macrophages. Additionally, resveratrol
treatment did also reduce the anti-inﬂammatory cytokine IL-10.
However our experiments also showed that resveratrol protects
against pro-inﬂammatory or cytotoxic molecules released into the
media by activated macrophages. Importantly the concentrations of
resveratrol that had an identiﬁable anti-inﬂammatory effect are
consistent with concentrations that can be found in the plasma (mM
levels) (Walker et al., 2014). In addition it is likely that resveratrol
metabolites, including resveratrol-3-sulfate also possess antiinﬂammatory activities that could provide further antiinﬂammatory activity (Walker et al., 2014).
Consistent with our ﬁndings, resveratrol reduced the levels of
IL-6, NO, and TNF-a in RAW264.7 cells (Yang et al., 2014). In this
study, the expression levels of high mobility group protein B1 and
toll-like receptor 4 were reduced following resveratrol treatment,
hinting at potential mechanisms involved in these antiinﬂammatory effects. Our study builds on these ﬁndings
providing a comprehensive view of the down-regulation of cytokines by resveratrol. A previous study identiﬁed that resveratrol
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similarly down-regulated MCP-1 mRNA, to reduce foam cell formation, potentially through up-regulation of AMP-activated protein kinase (AMPK) and sirtuin-1 (Dong et al., 2014). Our data
together with that of others is therefore generating a picture of the
broad anti-inﬂammatory actions of resveratrol. Such broad and
potent anti-inﬂammatory activities have led to proposals of
resveratrol treatment for diverse conditions, including cancer (Jang
et al., 1997), pain (Gentilli et al., 2001), neurodegenerative disease
(Virgili and Contestabile, 2000), obesity (Baur et al., 2006), diabetes
(Su et al., 2006), rheumatoid arthritis (Elmali et al., 2007) and
depression (Xu et al., 2010). However, there are also examples in
which resveratrol dietary supplementation worsened clinical
severity, for example in viral and autoimmune mouse models of
multiple sclerosis (Sato et al., 2013), suggesting that resveratrol
would make a poor option for therapeutic treatment of demyelinating diseases. In addition, our data suggest that there is a narrow
therapeutic window for resveratrol with higher levels contributing
to cytotoxicity. The design of the study focuses on the protective
effects of resveratrol in reducing pro-inﬂammatory cytokines and
the release of soluble cytotoxic factors but it must also be noted that
there are many putative beneﬁcial biological roles of activation of
these cells. For example, activation of microglia allows the removal
of toxic aggregates and cellular debris and the effects of resveratrol
in vivo must be tempered with the possibility that local immune
suppression contributes to neurodegeneration (Kan et al., 2015).
Similarly, as a counter to the reductions in pro-inﬂammatory cytokines by resveratrol treatment, it must be noted that resveratrol
also inhibited the release of the anti-inﬂammatory cytokine, IL-10,
and had a limited effect on chemokine release. A recent study using
hippocampal astrocytes identiﬁed a role for resveratrol in downregulating TNF-a, IL-1b, IL-6 and IL-10 in astrocytes following LPS
activation (Bellaver et al., 2015). The mechanisms identiﬁed were
similar to those in neurons and involved NF-kB, p38 and MAPK
signalling (Bellaver et al., 2015). Other mechanisms proposed for
the protective effects of resveratrol in primary astrocytes are
reviewed in (Quincozes-Santos and Gottfried, 2011). For example,
changes in glutamate handling (Vieira de Almeida et al., 2007) and
protection via the activation of nuclear factor erythroid 2-related
factor 2 (Erlank et al., 2011), a transcription factor that protects
astrocytes against glutathione reduction and oxidative stress
(Steele et al., 2013a, 2013b) have been implicated. Future in vivo
studies and co-culture experiments will help to delineate the speciﬁc roles of individual cytokines and chemokines in distinct cell
types in mediating neurodegenerative and neuroprotective
mechanisms.
4.3. Effects of resveratrol in vivo and its potential as a
neuroprotective agent
An in-depth study of the levels of inﬂammatory markers in
humans following resveratrol ingestion has not yet been carried
out. However, consistent with our ﬁndings of a large downregulation of pro-inﬂammatory molecules, a small study using an
extract of Polygonum Cuspidatum (containing 40 mg resveratrol)
taken daily for 6 weeks did lead to the reduction of plasma concentrations of TNF-a and IL-6 (Ghanim et al., 2010). In a recent
study in a mouse model of familial Alzheimer's disease, long-term
resveratrol treatment reduced amyloid and prevented memory
loss, potentially via activation of sirtuin-1 and AMPK signalling
pathways (Porquet et al., 2014). Surprisingly this occurred even
following an increase in IL-1b and TNF-a. Potent anti-inﬂammatory
activity for resveratrol has now been identiﬁed in a number of
disease models in mice, including reduced lung inﬂammation
through increasing superoxide dismutase, glutathione peroxidase,
and catalase activity by enhancing nuclear translocation of NF-kB

and heme oxygenase-1 activity (Liu et al., 2014). Multiple mechanisms for the neuroprotective activity of resveratrol have been
identiﬁed (reviewed in (Renaud and Martinoli, 2014)). Suggested
mechanisms for resveratrol in protecting neurons against Alzheimer's disease include by preventing oxidative stress and toxic
amyloid aggregation (Ladiwala et al., 2010; Shariatizi et al., 2015)
and this could occur by augmentation in the expression and activity
of anti-oxidant enzymes, such as catalase and superoxide dismutase (Sadi and Konat, 2015). Other ﬁndings have highlighted a
mechanism of action for resveratrol in activating sirtuin-1 to inhibit
p53 transcription and enhance neuroprotection (Feng et al., 2015)
or via MAPKs, NF-kB and nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH oxidase) signalling pathways (Zhang
et al., 2010).
We have previously shown that resveratrol has pro-energetic
effects in Neuro2a cells with the ability to increase ATP and GTP
levels in the cells (Nguyen et al., 2013). In line with this, resveratrol increased cell viability, an effect that was most evident in
cells treated with high levels of the NO donor but not in the
absence of NO (Figs. 2, 4 and 5). NO is a potent activator of AMPK
and in turn AMPK protects cells against the damaging effects of
NO; in pancreatic b cells this mechanism involves activation of
inositol-requiring enzyme 1 (Meares et al., 2011). During disruption of energy homeostasis AMPK is activated by an increased
AMP/ATP ratio (Sanders et al., 2007). In pancreatic b cells AMPK
activation by NO improved metabolic function of b-cells to prevent
cell death following NO treatment (Sanders et al., 2007). Resveratrol did not increase the energy charge potential (a measure of
energy status of the cell) of Neuro2a cells in conditions of sufﬁcient nutrition but only during starvation conditions (Nguyen
et al., 2013). Our current results suggest that resveratrol is also
protective under conditions of nitrosative stress in Neuro2a cells.
Our data do not support a role for resveratrol in direct scavenging
of nitric oxide (Figs. 2, 4 and 5) but rather suggest it promotes a
cytoprotective pathway. Thus it is possible that resveratrol promotes cell survival of Neuro2a cells against NO-mediated cell
death via the activation of AMPK, in addition to its antiinﬂammatory effects.
An important issue in considering resveratrol as a potential
neuroprotective agent is whether it can exert functional effects in
the brain following peripheral administration or ingestion. In line
with this consideration, brain inﬂammation caused by streptozotocin injections induced cognitive impairment in rats, yet memory
performance was enhanced following peripheral resveratrol
administration (Sharma and Gupta, 2002). In mice, resveratrol
administration upregulated sirtuin-1 to protect neurons against
neurodegeneration in models of Alzheimer's disease and motor
neurone disease (Kim et al., 2007). These ﬁndings have now been
conﬁrmed in adult primates, in which dietary resveratrol treatment (200 mg/kg/day) for 18 months increased working memory
and cognitive performance (Dal-Pan et al., 2011). Importantly,
these studies have recently been extended to humans and a picture of the neuroprotective effects of resveratrol in aging adults is
emerging. Following 26 weeks of resveratrol intake (200 mg/day)
older adults showed signiﬁcant increases in hippocampal functional connectivity and memory performance, demonstrating an
increased retention of words (Witte et al., 2014). We have studied
the effects of nitric oxide and inﬂammation on Neuro2a cell
viability. Technical developments in generating the many distinct
cell types of the brain using induced pluripotent stem cells will
provide a more accurate model of the human nervous system
in vitro (Ooi et al., 2013b). Future studies will capitalise on these
advancements to identify the contribution of distinct cell types
and molecular mechanisms involved in neuroprotection and
neurodegeneration.
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5. Conclusions
The ﬁndings from our study suggest that resveratrol has broad
anti-inﬂammatory effects and is capable of down-regulating proinﬂammatory responses in cellular models of both CNS-resident
microglia and CNS-inﬁltrating peripheral macrophages. Our ﬁndings provide further evidence of the neuroprotective potential of
resveratrol during neuroinﬂammation.
Acknowledgements
This research was funded by research grants from the National
Health & Medical Research Council (APP1071250) of Australia, The
Brain Foundation and The Rebecca Cooper Foundation.
References
Balez, R., Ooi, L., 2015. Getting to NO Alzheimer's disease: neuroprotection versus
neurotoxicity mediated by nitric oxide. Oxidative Med. Cell. Longev. Article ID
278164, (in press).
Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V.,
Allard, J.S., Lopez-Lluch, G., Lewis, K., Pistell, P.J., Poosala, S., Becker, K.G.,
Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K.W., Spencer, R.G.,
Lakatta, E.G., Le Couteur, D., Shaw, R.J., Navas, P., Puigserver, P., Ingram, D.K., de
Cabo, R., Sinclair, D.A., 2006. Resveratrol improves health and survival of mice
on a high-calorie diet. Nature 444, 337e342.
Bellaver, B., Souza, D., Bobermin, L., Souza, D., Gonçalves, C.-A., Quincozes-Santos, A.,
2015. Resveratrol protects hippocampal astrocytes against LPS-induced
neurotoxicity through HO-1, p38 and ERK pathways. Neurochem. Res. 40,
1600e1608.
Brantley, E.C., Guo, L., Zhang, C., Lin, Q., Yokoi, K., Langley, R.R., Kruzel, E., Maya, M.,
Kim, S.W., Kim, S.-J., Fan, D., Fidler, I.J., 2010. Nitric oxide-mediated Tumoricidal
activity of murine microglial cells. Transl. Oncol. 3, 380e388.
Carson, M., Bilousova, T., Puntambekar, S., Melchior, B., Doose, J., Ethell, I., 2007.
A rose by any other name? the potential consequences of microglial heterogeneity during CNS health and disease. Neurotherapeutics 4, 571e579.
Dal-Pan, A., Pifferi, F., Marchal, J., Picq, J.-L., Aujard, F., on behalf of RC, 2011.
Cognitive performances are selectively enhanced during chronic caloric restriction or resveratrol supplementation in a primate. PLoS ONE 6, e16581.
Dong, W., Wang, X., Bi, S., Pan, Z., Liu, S., Yu, H., Lu, H., Lin, X., Wang, X., Ma, T.,
Zhang, W., 2014. Inhibitory effects of resveratrol on foam cell formation are
mediated through monocyte chemotactic protein-1 and lipid metabolismrelated proteins. Int. J. Mol. Med. 33, 1161e1168.
Elmali, N., Baysal, O., Harma, A., Esenkaya, I., Mizrak, B., 2007. Effects of resveratrol
in inﬂammatory arthritis. Inﬂammation 30, 1e6.
Erlank, H., Elmann, A., Kohen, R., Kanner, J., 2011. Polyphenols activate Nrf2 in astrocytes via H2O2, semiquinones, and quinones. Free Radic. Biol. Med. 51,
2319e2327.
Feng, Y., Liu, T., Dong, S.-Y., Guo, Y.-J., Jankovic, J., Xu, H., Wu, Y.-C., 2015. Rotenone
affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9
acetylation in SH-SY5Y cells. J. Neurochem. 134, 668e676.
Gamper, N., Ooi, L., 2015 Feb 20. Redox and nitric oxide-mediated regulation of
sensory neuron ion channel function. Antioxid. Redox Signal. 22 (6), 486e504.
Gentilli, M., Mazoit, J.X., Bouaziz, H., Fletcher, D., Casper, R.F., Benhamou, D.,
Savouret, J.-F., 2001. Resveratrol decreases hyperalgesia induced by carrageenan
in the rat hind paw. Life Sci. 68, 1317e1321.
Ghanim, H., Sia, C.L., Abuaysheh, S., Korzeniewski, K., Patnaik, P., Marumganti, A.,
Chaudhuri, A., Dandona, P., 2010. An Antiinﬂammatory and reactive oxygen
species suppressive effects of an extract of polygonum cuspidatum containing
resveratrol. J. Clin. Endocrinol. Metabolism 95, E1eE8.
Guillemin, G.J., Brew, B.J., 2004. Microglia, macrophages, perivascular macrophages,
and pericytes: a review of function and identiﬁcation. J. Leukoc. Biol. 75,
388e397.
Heneka, M.T., Kummer, M.P., Latz, E., 2014. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463e477.
Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W.W.,
Fong, H.H.S., Farnsworth, N.R., Kinghorn, A.D., Mehta, R.G., Moon, R.C.,
Pezzuto, J.M., 1997. Cancer chemopreventive activity of resveratrol, a natural
product derived from grapes. Science 275, 218e220.
Jayasena, T., Poljak, A., Smythe, G., Braidy, N., Münch, G., Sachdev, P., 2013. The role
of polyphenols in the modulation of sirtuins and other pathways involved in
Alzheimer's disease. Ageing Res. Rev. 12, 867e883.
Kan, M.J., Lee, J.E., Wilson, J.G., Everhart, A.L., Brown, C.M., Hoofnagle, A.N.,
Jansen, M., Vitek, M.P., Gunn, M.D., Colton, C.A., 2015. Arginine deprivation and
immune suppression in a mouse model of Alzheimer's disease. J. Neurosci. 35,
5969e5982.
Karunaweera, N., Raju, R., Gyengesi, E., Muench, G., 2015. Plant polyphenols as inhibitors of NF-kB induced cytokine production e a potential anti-inﬂammatory
treatment for Alzheimer's disease? Front. Mol. Neurosci. 8.
Kettenmann, H., Hanisch, U.K., Noda, M., Verkhratsky, A., 2011. Physiology of

53

microglia. Physiol. Rev. 91, 461e553.
Kim, D., Nguyen, M.D., Dobbin, M.M., Fischer, A., Sananbenesi, F., Rodgers, J.T.,
Delalle, I., Baur, J.A., Sui, G., Armour, S.M., Puigserver, P., Sinclair, D.A., Tsai, L.H.,
2007. SIRT1 Deacetylase Protects against Neurodegeneration in Models for
Alzheimer's Disease and Amyotrophic Lateral Sclerosis.
Kraft, A.D., Harry, G.J., 2011. Features of microglia and neuroinﬂammation relevant
to environmental exposure and neurotoxicity. Int. J. Environ. Res. Public Health
8, 2980e3018.
Ladiwala, A.R.A., Lin, J.C., Bale, S.S., Marcelino-Cruz, A.M., Bhattacharya, M.,
Dordick, J.S., Tessier, P.M., 2010. Resveratrol selectively remodels soluble Oligomers and Fibrils of amyloid Ab into Off-pathway conformers. J. Biol. Chem.
285, 24228e24237.
Lawson, L.J., Perry, V.H., Dri, P., Gordon, S., 1990. Heterogeneity in the distribution
and morphology of microglia in the normal adult mouse brain. Neuroscience
39, 151e170.
Lawson, L.J., Perry, V.H., Gordon, S., 1992. Turnover of resident microglia in the
normal adult mouse brain. Neuroscience 48, 405e415.
Liu, H., Ren, J., Chen, H., Huang, Y., Li, H., Zhang, Z., Wang, J., 2014. Resveratrol
protects against cigarette smokeeinduced oxidative damage and Pulmonary
inﬂammation. J. Biochem. Mol. Toxicol. 28, 465e471.
Luo, X.-G., Chen, S.-D., 2012. The changing phenotype of microglia from homeostasis to disease. Transl. Neurodegener. 1, 9.
McCoy, M.K., Tansey, M.G., 2008. TNF signaling inhibition in the CNS: implications
for normal brain function and neurodegenerative disease. J. Neuroinﬂammation
5, 45.
Meares, G.P., Hughes, K.J., Naatz, A., Papa, F.R., Urano, F., Hansen, P.A.,
Benveniste, E.N., Corbett, J.A., 2011. IRE1-Dependent activation of AMPK in
response to nitric oxide. Mol. Cell. Biol. 31, 4286e4297.
Mitchell, J.A., Warner, T.D., 2006. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inﬂammatory drugs. Nat. Rev.
Drug Discov. 5, 75e86.
Münch, G., Gasic-Milenkovic, J., Dukic-Stefanovic, S., Kuhla, B., Heinrich, K.,
Riederer, P., Huttunen, H., Founds, H., Sajithlal, G., 2003. Microglial activation
induces cell death, inhibits neurite outgrowth and causes neurite retraction of
differentiated neuroblastoma cells. Exp. Brain Res. 150, 1e8.
Nguyen, N.T.Q., Ooi, L., Piller, S.C., Münch, G., 2013. Proenergetic effects of resveratrol in the murine neuronal cell line Neuro2a. Mol. Nutr. Food Res. 57,
1901e1907.
Norden, D.M., Muccigrosso, M.M., Godbout, J.P., 2015 Sep. Microglial priming and
enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and
neurodegenerative disease. Neuropharmacology 96 (Pt A), 29e41.
Ooi, L., Gigout, S., Pettinger, L., Gamper, N., 2013a. Triple cysteine module within Mtype K(þ) channels mediates reciprocal channel modulation by nitric oxide and
reactive oxygen species. J. Neurosci. ofﬁcial J. Soc. Neurosci. 33, 6041e6046.
Ooi, L., Sidhu, K., Poljak, A., Sutherland, G., O'Connor, M., Sachdev, P., Münch, G.,
2013b. Induced pluripotent stem cells as tools for disease modelling and drug
discovery in Alzheimer's disease. J. Neural Transm. 120, 103e111.
~
, C., Ferrer, I., Camins, A., Sanfeliu, C., Del Valle, J., Palla
s, M.,
Porquet, D., Grin
an-Ferre
2014. Neuroprotective role of trans-resveratrol in a murine model of familial
Alzheimer's disease. J. Alzheimers Dis. 42, 1209e1220.
Quincozes-Santos, A., Gottfried, C., 2011. Resveratrol modulates astroglial functions:
neuroprotective hypothesis. Ann. N. Y. Acad. Sci. 1215, 72e78.
Renaud, J., Martinoli, M.G., 2014. Resveratrol as a protective molecule for neuroinﬂammation: a review of mechanisms. Curr. Pharm. Biotechnol. 15, 318e329.
Sadi, G., Konat, D., 2015. Resveratrol regulates oxidative biomarkers and antioxidant
enzymes in the brain of streptozotocin-induced diabetic rats. Pharm. Biol. 1e8.
Sanders, Matthew J., Grondin, Pascal O., Hegarty, Bronwyn D., Snowden, Michael A.,
Carling, D., 2007. Investigating the mechanism for AMP activation of the AMPactivated protein kinase cascade. Biochem. J. 403, 139e148.
Sato, F., Martinez, N.E., Shahid, M., Rose, J.W., Carlson, N.G., Tsunoda, I., 2013.
Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. Am. J. Pathology 183, 1390e1396.
Schmid, C.D., Melchior, B., Masek, K., Puntambekar, S.S., Danielson, P.E., Lo, D.D.,
Gregor Sutcliffe, J., Carson, M.J., 2009. Differential gene expression in LPS/IFNg
activated microglia and macrophages: in vitro versus in vivo. J. Neurochem. 109,
117e125.
Shariatizi, S., Meratan, A.A., Ghasemi, A., Nemat-Gorgani, M., 2015. Inhibition of
amyloid ﬁbrillation and cytotoxicity of lysozyme ﬁbrillation products by polyphenols. Int. J. Biol. Macromol. 80, 95e106.
Sharma, M., Gupta, Y.K., 2002. Chronic treatment with trans resveratrol prevents
intracerebroventricular streptozotocin induced cognitive impairment and
oxidative stress in rats. Life Sci. 71, 2489e2498.
Simard, A.R., Soulet, D., Gowing, G., Julien, J.-P., Rivest, S., 2006. Bone Marrowderived microglia play a critical role in restricting senile Plaque formation in
Alzheimer's disease. Neuron 49, 489e502.
Singh, U.P., Singh, N.P., Singh, B., Hofseth, L.J., Price, R.L., Nagarkatti, M.,
Nagarkatti, P.S., 2010. Resveratrol (Trans-3,5,40 -trihydroxystilbene) induces silent mating type information Regulation-1 and down-regulates nuclear transcription factor-kB activation to Abrogate Dextran sulfate sodium-induced
colitis. J. Pharmacol. Exp. Ther. 332, 829e839.
Steele, M., Fuller, S., Maczurek, A., Kersaitis, C., Ooi, L., Münch, G., 2013a. Chronic
inﬂammation Alters production and release of glutathione and related thiols in
human U373 astroglial cells. Cell Mol. Neurobiol. 33, 19e30.
Steele, M.L., Fuller, S., Patel, M., Kersaitis, C., Ooi, L., Münch, G., 2013b. Effect of Nrf2
activators on release of glutathione, cysteinylglycine and homocysteine by

54

N. Steiner et al. / Neurochemistry International 95 (2016) 46e54

human U373 astroglial cells. Redox Biol. 1, 441e445.
Su, H.-C., Hung, L.-M., Chen, J.-K., 2006. Resveratrol, a Red Wine Antioxidant, Possesses an Insulin-like Effect in Streptozotocin-induced Diabetic Rats.
Vane, J.R., Bakhle, Y.S., Botting, R.M., 1998. Cycloygenases1 and 2. Annu. Rev.
Pharmacol. Toxicol. 38, 97e120.
~ eiro, C., Leite, M., Brolese, G., Tramontina, F., Feoli, A.,
Vieira de Almeida, L., Pin
Gottfried, C., Gonçalves, C.-A., 2007. Resveratrol increases glutamate uptake,
glutathione content, and S100B secretion in cortical astrocyte cultures. Cell Mol.
Neurobiol. 27, 661e668.
Virgili, M., Contestabile, A., 2000. Partial neuroprotection of in vivo excitotoxic brain
damage by chronic administration of the red wine antioxidant agent, transresveratrol in rats. Neurosci. Lett. 281, 123e126.
Walker, J., Schueller, K., Schaefer, L.-M., Pignitter, M., Esefelder, L., Somoza, V., 2014.
Resveratrol and its metabolites inhibit pro-inﬂammatory effects of lipopolysaccharides in U-937 macrophages in plasma-representative concentrations.

Food Funct. 5, 74e84.
€ el, A., 2014. Effects of resveratrol on memory
Witte, A.V., Kerti, L., Margulies, D.S., Flo
performance, hippocampal functional connectivity, and glucose metabolism in
healthy older adults. J. Neurosci. 34, 7862e7870.
Xu, Y., Wang, Z., You, W., Zhang, X., Li, S., Barish, P.A., Vernon, M.M., Du, X., Li, G.,
Pan, J., Ogle, W.O., 2010. Antidepressant-like effect of trans-resveratrol:
involvement of serotonin and noradrenaline system. Eur. Neuropsychopharmacol. 20, 405e413.
Yang, Y., Li, S., Yang, Q., Shi, Y., Zheng, M., Liu, Y., Chen, F., Song, G., Xu, H., Wan, T.,
He, J., Chen, Z., 2014. Resveratrol reduces the proinﬂammatory effects and
lipopolysaccharide- induced expression of HMGB1 and TLR4 in RAW264.7 cells.
Cell. Physiol. Biochem. 33, 1283e1292.
Zhang, F., Liu, J., Shi, J.S., 2010. Anti-inﬂammatory activities of resveratrol in the
brain: role of resveratrol in microglial activation. Eur. J. Pharmacol. 636, 1e7.

